200 mg/m2 melphalan—the gold standard for multiple myeloma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2010.104.pdf
Reference10 articles.
1. Palumbo, A. et al. Melphalan 200 mg/m2 vs melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 115, 1873–1879 (2010).
2. Moreau, P. et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 99, 731–735 (2002).
3. Cavo, M. et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 112, a158 (2008).
4. Harousseau, J. L. et al. Velcade/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial [abstract]. Blood 110, a450 (2007).
5. Chanan-Khan, A. A. & Giralt, S. Importance of achieving a complete response in multiple myeloma and the impact of novel agents. J. Clin. Oncol. 28, 2612–2624 (2010).
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience;eJHaem;2024-08-19
2. Steady‐state versus chemotherapy‐based hematopoietic cell mobilization after anti‐CD38‐based induction therapy in newly diagnosed multiple myeloma;Transfusion;2023-10-18
3. The First 100-day Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients: Melphalan 200 mg/m² versus 140 mg/m² Conditioning Regimen;Turkish Journal of Clinics and Laboratory;2023-09-30
4. Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience;Leukemia & Lymphoma;2023-06-01
5. The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma;International Journal of Molecular Sciences;2022-12-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3